Hormone combo shows promise against resistant prostate cancer
NCT ID NCT03516812
First seen Oct 01, 2025 · Last updated May 09, 2026 · Updated 25 times
Summary
This study tested a new combination treatment for men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The treatment uses testosterone (given as shots) along with a drug called olaparib, which blocks cancer cells from repairing damage. The goal was to see if this combination could lower PSA levels, a marker of prostate cancer activity. The study enrolled 36 men and has been completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.